Financial Review: Black Titan (BTTC) versus Its Competitors

Black Titan (NASDAQ:BTTC) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its competitors? We will compare Black Titan to similar businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Risk and Volatility

Black Titan has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s competitors have a beta of 0.54, meaning that their average share price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Black Titan and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	97	199	217	14	2.28

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 130.59%. Given Black Titan’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Black Titan has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Black Titan and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.58
Black Titan Competitors	$233.85 million	-$55.65 million	-10.78

Black Titan’s competitors have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

56.4% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 0.7% of Black Titan shares are owned by insiders. Comparatively, 16.4% of shares of all “Services – Computer Programming And Data Processing” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Black Titan and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-37.96%	-997.94%	-64.24%

Summary

Black Titan competitors beat Black Titan on 8 of the 13 factors compared.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.